Literature DB >> 15696436

Hypercalcemia due to excess 1,25-dihydroxyvitamin D in Crohn's disease.

Kathryn A Tuohy1, Theodore I Steinman.   

Abstract

Hypercalcemia has been described in patients with a number of granulomatous diseases, including sarcoidosis and mycobacterial infection. Disordered vitamin D metabolism is the root cause for the elevated serum calcium levels. A similar mechanism of abnormal vitamin D metabolism explained the hypercalcemia occurring in patients with lymphoma. Crohn's disease is a granulomatous disorder that is more commonly associated with hypocalcemia caused by poor calcium intake and decreased intestinal calcium absorption related to vitamin D deficiency as a consequence of malabsorption. A man with Crohn's disease who presented with hypercalcemia and acute renal failure is described. Biochemical parameters showed an elevated 1,25-dihydroxyvitamin D level, with a low-normal 25-hydroxyvitamin D level and decreased parathyroid hormone level. Inflammatory bowel disease had been clinically active during the preceding 2 months. With resolution of gastrointestinal symptoms, serum calcium, vitamin D, and parathyroid hormone levels returned to normal. Serum creatinine levels decreased toward normal. Angiotensin-converting enzyme (ACE) levels have been reported to be elevated in patients with sarcoidosis, particularly in the setting of active disease with hypercalcemia. Controversy exists about ACE levels in the face of active Crohn's disease: 1 report noted elevated levels, whereas other publications reported depressed levels. Our patient had an elevated ACE level in the setting of active bowel disease and hypercalcemia, and ACE levels returned to normal with resolution of gastrointestinal symptoms.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15696436     DOI: 10.1053/j.ajkd.2004.09.008

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  11 in total

1.  Juvenile sarcoidosis presenting as Crohn's disease.

Authors:  Jürgen Brunner; Consolato Sergi; Thomas Müller; Ingmar Gassner; Friederike Prüfer; Lothar Bernd Zimmerhackl
Journal:  Eur J Pediatr       Date:  2006-03-18       Impact factor: 3.183

2.  Solar ultraviolet-B irradiance and vitamin D may reduce the risk of septicemia.

Authors:  William B Grant
Journal:  Dermatoendocrinol       Date:  2009-01

3.  Rennies, Crohn's disease and severe hypercalcaemia.

Authors:  Filip Zemrak; Lisa McNeil; Norman Peden
Journal:  BMJ Case Rep       Date:  2010-12-20

Review 4.  Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment.

Authors:  Peter J Tebben; Ravinder J Singh; Rajiv Kumar
Journal:  Endocr Rev       Date:  2016-09-02       Impact factor: 19.871

Review 5.  Not enough vitamin D: health consequences for Canadians.

Authors:  Gerry Schwalfenberg
Journal:  Can Fam Physician       Date:  2007-05       Impact factor: 3.275

Review 6.  The paradoxical effects of vitamin D on type 1 mediated immunity.

Authors:  Margherita T Cantorna; Sanhong Yu; Danny Bruce
Journal:  Mol Aspects Med       Date:  2008-05-04

Review 7.  [Inflammation of the parathyroid glands].

Authors:  S Ting; S Synoracki; S-Y Sheu; K W Schmid
Journal:  Pathologe       Date:  2016-05       Impact factor: 1.011

8.  Oral vitamin D3 supplementation reduces monocyte-derived dendritic cell maturation and cytokine production in Crohn's disease patients.

Authors:  Lars E Bartels; Mia Bendix; Christian L Hvas; Søren P Jørgensen; Jørgen Agnholt; Ralf Agger; Jens F Dahlerup
Journal:  Inflammopharmacology       Date:  2013-12-29       Impact factor: 4.473

9.  GRANULOMATOUS DISEASE OF UNUSUAL SITES CAUSING HYPERCALCEMIA: TWO CASE REPORTS.

Authors:  Stamatios Zouras; Ashutosh Surya; Hussam Abusahmin; Mohamed Hassan; Emyr Humphreys; Pramod Nagaraja; Joanna Hurley; Elizabeth Slowinska; Gautam Das
Journal:  AACE Clin Case Rep       Date:  2019-01-30

Review 10.  Hypercalcemic Disorders in Children.

Authors:  Victoria J Stokes; Morten F Nielsen; Fadil M Hannan; Rajesh V Thakker
Journal:  J Bone Miner Res       Date:  2017-11-02       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.